三阴性乳腺癌新辅助化疗中铂类的地位
Role of platinum in new adjuvant chemotherapy of triple negative breast cancer

三阴性乳腺癌（TNBC）作为乳腺癌的一个特殊亚型，对靶向治疗及内分泌治疗不敏感，具有侵袭 性强、复发率较高、总生存率低等生物学特征。新辅助化疗是治疗TNBC的有效手段，但是并没有获得理想的预 后改善，并且存在化疗药物耐药的问题。铂类药物是目前临床上使用最广泛的抗癌药物之一，在TNBC治疗方面 表现优异，无论单药或联合化疗对提高TNBC患者病理完全缓解、改善预后均具有潜在价值。本文就铂类药物在 TNBC新辅助化疗中的地位作一概述，为提高TNBC的临床治疗效果提供证据支持。
As a special subtype of breast cancer, triple negative breast cancer (TNBC) is insensitive to targeted therapy and endocrine therapy, with strong invasiveness, high recurrence rate and low overall survival. New adjuvant chemotherapy is efficient to TNBC, but does not achieve ideal prognostic improvement. Meanwhile, resistance to chemotherapy drugs significantly affects the treatment of TNBC patients. So far, as one of the most popular anticancer drugs, platinum exerts excellent efficacy in TNBC treatment. Both platinum alone and combination chemotherapy have promising values in improving the pathological complete response and prognosis obviously. Here we review the application of platinum in the new adjuvant chemotherapy of TNBC, thus providing more evidential support to the clinical treatment of TNBC